Health Condition 1: E139- Other specified diabetes mellituswithout complications Health Condition 2: E119- Type 2 diabetes mellitus without complications
Conditions
Interventions
Intervention1: GLUCOTAS
Each GLUCOTAS 300 mg Capsule contains: CGA (Chlorogenic Acid) + MSM (Methylsulfonylmethane) + Bio-M + Glycine: Dosage: 2 Capsule TID after food for 90 days
Control Intervention
Sponsors
Zoom Technologies Inc
Eligibility
Inclusion criteria
Inclusion criteria: 1. All patients with duly filled in ICFs [Informed Consent Forms] 2. Treatment naive Type 2 Diabetes or Type 2 Diabetes on monotherapy 3. Hba1c level should be = 5.7 and = 7 4. BMI should be = 25 kg/m2 and = 45 kg/m2 5. Absence of any oral antidiabetic drug or any injectable antidiabetic therapy. 6. WOCBP (Women of Childbearing Potential) must be willing to use double barrier contraception for the entire study duration. 7. Patients full filling all inclusion criteria and none of exclusion criteria will be enrolled.
Exclusion criteria
Exclusion criteria: 1. History of Type-1 diabetes mellitus or history of ketoacidosis. 2. Patients already on Insulin therapy. 3. Patients already on oral anti-diabetic drug therapy. 4. NYHF (New York Heart Association) Class III–IV heart failure. 5. History of coronary angioplasty, coronary stent placement, coronary bypass surgery, myocardial infarction, stroke or transient ischemic attack in the previous 3 months. 6. Pregnancy or lactating women. 7. Patients known or thought to be hypersensitivity to the investigational products. 8. Any medication or indication that might point to an increased risk, associated with study participation or Investigational Product administration or may interfere with the interpretation of study results and, in the judgment of the study personnel, would make the subject inappropriate for inclusion. 9. Participation in other clinical trials in the last three months and during study participation. 10. Patients with severe renal impairment, including those receiving dialysis. 11. Patients with active liver disease, including those with primary biliary cirrhosis and unexplained persistent liver function. 12. Patient not willing to fill Informed consent form.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| •Percentage (%) change of mean HbA1c at the end of 90 days from base line. •Percentage (%) change of mean Weight at the end of 90 days from base line •Number of & Nature of adverse events arising out of treatment of patients with the medication & their causal relationship to study medication. •Subjects will also be questioned about the occurrence of anticipated side effects of both treatment arm. •Any significant changes in laboratory values of subjects compared to their baseline values. Timepoint: 90 days | — |
Secondary
| Measure | Time frame |
|---|---|
| Percentage (%) change of mean FBG & 2-hour PPBG levels from baseline to the end of treatment.Timepoint: 90 days | — |
Countries
India
Contacts
Public ContactSoumya Ranjan Dey
Hi-Tech Medical College and Hospital
Outcome results
None listed